Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

May 02, 2013 10:00 ET

Trimel to Report First Quarter 2013 Results and Host Investor Call

TORONTO, ONTARIO--(Marketwired - May 2, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) will report its first quarter financial results for the period ended March 31, 2013 on Wednesday, May 8, 2013 after the market closes.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, May 9, 2013, at 8:30 a.m. Eastern Daylight Time.

To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.) or 1- 800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Thursday, May 16, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 3086288#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Contact Information